Cencora

Cencora Raises Price Target to $417 as JPMorgan Boosts Estimate Following Financial Model Update

Cencora Expands Global Pharmaceutical Logistics Capabilities with New Investments in US and Europe

科塞特不动产

Cencora's 15min chart signals RSI Oversold, KDJ Golden Cross.

Assessing Cencora's Value Amid 64% Rally in 2025: DCF Analysis and Valuation Breakdown

Cencora's 15-min chart shows RSI overbought and KDJ death cross.

Catalyst<ul> <li>Most analysts rate COR Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Net outflows across all fund sizes indicate reduced institutional confidence in COR.</li></ul>

Key Factors

JPMorgan raised Cencora's (COR) price target to $417 from $344 following a financial model update and improved guidance. Cencora (COR) plans to invest $1 billion through 2030 to strengthen its U.S. pharmaceutical supply chain and logistics infrastructure. Cencora (COR) raised its quarterly dividend by 9% to $0.60 per share and updated long-term guidance for adjusted operating income and EPS growth.

COR News